Pioglitazone

BED PKG FE NO MATTRESS FDA FR LUMEX

BED PKG FE NO MATTRESS FDA HR LUMEX

BREAST CARCINOMA Controls /Pk (25)

Derivative of PGF1&alpha containing a thio-fluorobenzene substituent in the lower side chain binds to the recombinant human FP receptor with an IC50 value of about 30 nM.

Derivative of PGF1&alpha containing a thio-fluorobenzene substituent in the lower side chain binds to the recombinant human FP receptor with an IC50 value of about 30 nM.

Derivative of PGF1&alpha containing an acetylenic fluorobenzene substituent in the lower side chain binds to the recombinant human FP receptor with an IC50 value of about 0.5 &microM.

Derivative of PGF1&alpha containing an acetylenic fluorobenzene substituent in the lower side chain binds to the recombinant human FP receptor with an IC50 value of about 0.5 &microM.

An 8-aza-9-oxo-15-hydroxy saturated analog of PGE2 selectively binds the EP4 receptor (Ki = 35 nM) relative to the EP1, EP2, and EP3 receptors (Ki = 3,000, 2,000, and &gt3,000 nM, respectively) stimulates cAMP formation in excised mouse ovaries.

An 8-aza-9-oxo-15-hydroxy saturated analog of PGE2 selectively binds the EP4 receptor (Ki = 35 nM) relative to the EP1, EP2, and EP3 receptors (Ki = 3,000, 2,000, and &gt3,000 nM, respectively) stimulates cAMP formation in excised mouse ovaries.

An 8-aza-9-oxo-15-hydroxy saturated analog of PGE2 selectively binds the EP4 receptor (Ki = 35 nM) relative to the EP1, EP2, and EP3 receptors (Ki = 3,000, 2,000, and &gt3,000 nM, respectively) stimulates cAMP formation in excised mouse ovaries.

An 8-aza-9-oxo-15-hydroxy saturated analog of PGE2 selectively binds the EP4 receptor (Ki = 35 nM) relative to the EP1, EP2, and EP3 receptors (Ki = 3,000, 2,000, and &gt3,000 nM, respectively) stimulates cAMP formation in excised mouse ovaries.

A potent, dual PI3K&alpha/mTOR inhibitor (IC₅₀s = 0.9 and 0.6 nM, respectively) inhibits MDA361 (breast) and PC3 (prostate) tumor cell growth (IC₅₀s = in vivo.